Bernstein raised the firm’s price target on CVS Health (CVS) to $91 from $87 and keeps a Market Perform rating on the shares. The firm sees a sector turnaround in the government managed care organization sector beginning in 2026, but expects to see bumps in the recovery. Bernstein believes all MCO sectors present attractive entry points, with Medicare Advantage likely to see the nearest term earnings improvements and Medicaid representing the most attractive valuations.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S.
- Trump Trade: Trump strikes deals with nine drugmakers to cut prices
- President Trump says he’ll meet with insurance companies on price cuts
- Consumers left in limbo as ACA subsidies are not renewed, WSJ says
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!